2011: Baxter International acquired Prism Pharmaceuticals for up to $338 mm and launched the Nexterone
This unique technology has enabled several FDA-approved products, including Amgen's Kyprolis, Baxter International's Nexterone
, Acrotech Biopharma's Evomela, Melinta Therapeutics' Baxdela, Sage Therapeutics' Zulresso, Merck and Co.'s Noxafil and Pfizer's Vfend.
Additionally, Baxter acquired Prism Pharmaceuticals for $170 million, and launched its lead product Nexterone
, a ready-to-use premixed IV container version of antarrythmic agent amiodarone.
, the first and only ready-to-use premixed intravenous
The purchase includes Prism's Nexterone
product portfolio and consists of a $170 million upfront payment at closing and as much as $168 million in future sales milestones, for a potential total of $338 million.